Erika Richtig
Erika Richtig
The 2018 ASCO Annual Meeting provided a closer look on the details of studies already presented. In melanoma, the interest was on neoadjuvant treatment options with high pathological response rates as well as updates on large phase III stud...
Current and evolving treatment strategies in adult immune thrombocytopenia [0.03%]
成人免疫性血小板减少症的当前和不断发展的治疗策略
Jan-Paul Bohn,Michael Steurer
Jan-Paul Bohn
Immune thrombocytopenia (ITP) is an acquired autoimmune phenomenon resulting in low platelet count and increased bleeding risk. Goals of upfront management include prompt control of severe bleeding-which is rare-as well as induction and mai...
Paul Knöbl
Paul Knöbl
Thrombotic thrombocytopenic purpura (TTP) is a clearly defined entity of the thrombotic microangiopathies (TMA), a heterogeneous group of disorders characterized by microangiopathic hemolytic anemia with red cell fragmentation, thrombocytop...
Zsuzsanna Bago-Horvath
Zsuzsanna Bago-Horvath
The 40th International San Antonio Breast Cancer Symposium offered a multifaceted platform for the presentation of several innovative therapeutic approaches. The results of these preclinical and clinical studies provided insight into the de...
Florian Fitzal
Florian Fitzal
This year there were three interesting oral presentations and several posters presenting important new data regarding local therapy (surgery and radiotherapy) as well as radiological aspects. This minireview is a personal view of the clinic...
SABCS 2017: lifestyle factors, hormone receptor-positive advanced disease, liquid biopsies, and prognosis [0.03%]
2017年圣安东尼奥乳腺癌大会（SABCS）亮点：生活方式因素、激素受体阳性晚期疾病、液体活检和预后
Gabriel Rinnerthaler,Simon Peter Gampenrieder,Richard Greil
Gabriel Rinnerthaler
This article reviews the clinically most relevant presentations at the San Antonio Breast Cancer Symposium (SABCS) 2017 on the topics lifestyle factors, hormone receptor-positive advanced disease, liquid biopsies, and prognosis. In a retros...
SABCS 2017: update on chemotherapy, targeted therapy, and immunotherapy [0.03%]
2017年圣安东尼奥乳腺癌大会聚焦化疗、靶向治疗和免疫治疗的新进展
Rupert Bartsch,Elisabeth Bergen
Rupert Bartsch
In the areas of chemotherapy, targeted therapy and immunotherapy, several interesting and clinically relevant data were presented at the 2017 San Antonio Breast Cancer Symposium (SABCS). This short review focuses on dose-dense and/or sequen...
Current concepts and future directions in neoadjuvant chemotherapy of breast cancer [0.03%]
乳腺癌新辅助化疗的当前概念及未来方向
Rupert Bartsch,Elisabeth Bergen,Arik Galid
Rupert Bartsch
Preoperative administration of chemotherapy is a widespread treatment approach in early stage breast cancer whenever chemotherapy is indicated in principle. In addition, neoadjuvant treatment is today regarded as the preferred way of delive...
Demystification of palliative care: what palliative care teams don't want you to think about them [0.03%]
揭穿缓和医疗的面纱：缓和医疗团队不希望您了解的情况
Eva K Masel,Gudrun Kreye
Eva K Masel
There is robust data that palliative care is prolonging life while there are still prejudices towards this discipline that have to be demystified. Patients, relatives and caregivers benefit from the concept of early integration of palliativ...
Long-term remission in advanced stage hepatocellular carcinoma? A chance for cure? [0.03%]
晚期肝细胞癌长期缓解的机会？治愈的希望？
Matthias Pinter,Wolfgang Sieghart
Matthias Pinter
Liver resection, transplantation, and local ablation are potential curative treatment options but can only be offered to patients with early stage hepatocellular carcinoma (HCC). Patients with macrovascular tumor invasion and extrahepatic m...